Lopinavir (DrugBank: Lopinavir)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 265 | Lipodystrophy | 5 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00865007 (ClinicalTrials.gov) | December 2008 | 18/3/2009 | Lopinavir/r Monotherapy Versus Abacavir/Lamivudine and Lopinavir/r for Limb Fat Recovery in Persons With Lipoatrophy | A Phase IV-III Comparative, Randomized, Open-label Study to Evaluate the Efficacy for the Recovery of Peripheral Fat (or of the Extremities) of Lopinavir/Ritonavir in Monotherapy Versus Abacavir/Lamivudine and Lopinavir/Ritonavir | HIV Infection;Lipodystrophy;HIV Infections | Drug: Monotherapy (Lopinavir/ritonavir);Drug: Monotherapy (Lopinavir/ritonavir) + ABC/3TC | Fundacion SEIMC-GESIDA | Abbott | Completed | 18 Years | N/A | Both | 88 | Phase 4 | Spain |
| 2 | NCT00192621 (ClinicalTrials.gov) | November 2004 | 12/9/2005 | Seronegatives and Metabolic Abnormalities Protocol 2 (SAMA002): Study to Compare the Effect of Kaletra and Combivir® in HIV-Negative Healthy Subjects | A 3 Arm, Prospective Study to Compare the Effect of 6 Weeks Exposure to the Combination of Lopinavir (LPVr)/Combivir® (AZT/3TC) Versus Lopinavir Alone or Combivir® Alone in HIV-negative Healthy Subjects on the Development of Abnormalities of Lipid and Glucose Metabolism | HIV Infections;Dyslipidemias;Glucose Metabolism Disorders;Metabolic Diseases;Lipodystrophy;Cardiovascular Disease | Drug: Combivir (zidovudine [AZT] / lamivudine [3TC]);Drug: Kaletra (lopinavir [LPVr]) | Kirby Institute | St Vincent's Hospital, Sydney;National Heart, Lung, and Blood Institute (NHLBI);Garvan Institute of Medical Research;Prince of Wales Hospital, Sydney | Completed | 18 Years | N/A | Both | 50 | Phase 4 | Australia |
| 3 | NCT00139178 (ClinicalTrials.gov) | March 2004 | 30/8/2005 | Switching From Zidovudine to an NNRTI or Lopinavir/Ritonavir in Patients Treated With Zidovudine/ Lamivudine/Abacavir. | Switching From Zidovudine to an NNRTI or Lopinavir/Ritonavir in Patients Treated With Zidovudine/ Lamivudine/Abacavir. Influence on Metabolic Abnormalities | HIV Associated Lipodystrophy Syndrome.;HIV;Hypercholesterolemia;Lipoatrophy | Drug: Different HAART regimens | Danish HIV Research Group | Odense University Hospital;Rigshospitalet, Denmark;Hvidovre University Hospital;Aarhus University Hospital | Completed | 18 Years | N/A | Both | 100 | Phase 4 | Denmark |
| 4 | NCT00122226 (ClinicalTrials.gov) | January 2003 | 14/7/2005 | MEDICLAS Study (Metabolic Effects of Different Classes of AntiretroviralS) | MEDICLAS Study (Metabolic Effects of Different Classes of AntiretroviralS) | HIV Infections;HIV-Associated Lipodystrophy Syndrome | Drug: Lopinavir/ritonavir + zidovudine + lamivudine;Drug: Lopinavir/ritonavir + nevirapine | VU University Medical Center | Abbott;Boehringer Ingelheim | Active, not recruiting | 18 Years | 70 Years | Male | 50 | Phase 4 | Finland;Netherlands;Spain;United Kingdom |
| 5 | NCT00028314 (ClinicalTrials.gov) | March 2002 | 20/12/2001 | Effects of Treatment Changes on Fat Wasting in the Arms and Legs of HIV Patients | A Restrictively Randomized, Open-Label, Controlled, Pilot Study of the Effect of a Thymidine Analogue Substitution or Change to a Nucleoside-Sparing Regimen on Peripheral Fat Wasting | HIV Infections;Lipodystrophy;Wasting Disease | Drug: Abacavir sulfate;Drug: Atazanavir/Ritonavir;Drug: Lopinavir/Ritonavir;Drug: Nevirapine | National Institute of Allergy and Infectious Diseases (NIAID) | NULL | Completed | 13 Years | N/A | Both | 150 | N/A | United States |